ASH 2015: Highs And Lows In CLL
This article was originally published in Scrip
A number of companies reported positive developments for products being developed for, or seeking label expansions in, chronic lymphatic leukemia (CLL) at the American Society of Hematology (ASH) annual meeting in Orlando, Florida, but Gilead Sciences kept the balance with a poor prognosis for Zydelig (idelalisib) as a future first-line agent.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.